Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer. 2010 Sep 1;116(17):4000-6. doi: 10.1002/cncr.25197.
Single-institution data suggest that treatment with radiation and axillary lymph node dissection (ALND) may be an appropriate alternative to mastectomy for T0N+ breast cancer. Population-based multi-institutional data supporting this approach are lacking.
The cause-specific survival (CSS) and overall survival (OS) of women with T0N+M0 ductal, lobular, or mixed breast cancer in the Surveillance, Epidemiology, and End Results database from 1983 to 2006 were analyzed. Groups were defined as: 1) no ALND, mastectomy, or RT (observation); 2) ALND only; 3) mastectomy plus ALND with or without postmastectomy radiation (Mast); and 4) breast-conserving therapy (BCT) with ALND and radiation (BCT).
In total, 750 of 770,030 patients with breast cancer had T0N+M0 disease (incidence, 0.10%), and 596 of those patients underwent ALND (79.5%). Patients who underwent Mast or BCT (n = 470) had a 10-year OS rate of 64.9% compared with 58.5% for patients who underwent ALND only (n = 126; P = .02) and 47.5% for patients who underwent observation only (n = 94; P = .04). The 10-year CSS rate was 75.7% for patients who underwent BCT versus 73.9% for patients who underwent Mast (P = .55). In multivariate analysis of CSS for patients who underwent Mast or BCT, the following factors were correlated with an unfavorable outcome: positive estrogen receptor status (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.24-0.96; P = .04), >/=10 positive lymph nodes (HR, 5.7; 95%CI, 2.4-13.4; P </= .01), and <10 resected lymph nodes (HR, 42.9; 95%CI, 1.2-7.1; P = .02). Mast did not improve CSS compared with BCT (HR, 1.09; 95%CI, 0.57-2.1; P = .79).
Definitive locoregional treatment with either Mast or BCT improved the outcome of patients with T0N+breast cancer, and no difference in survival was observed between the treatments. Cancer 2010. (c) 2010 American Cancer Society.
单机构数据表明,对于 T0N+乳腺癌,放射治疗和腋窝淋巴结清扫(ALND)联合治疗可能是乳房切除术的一种替代方案。目前缺乏支持这一方法的基于人群的多机构数据。
对 1983 年至 2006 年间监测、流行病学和最终结果数据库中 T0N+M0 导管、小叶或混合乳腺癌女性的特定病因生存率(CSS)和总生存率(OS)进行分析。组定义为:1)无 ALND、乳房切除术或放疗(观察);2)仅 ALND;3)乳房切除术加 ALND 伴或不伴乳房切除术后放疗(Mast);4)保乳治疗(BCT)联合 ALND 和放疗。
总共 770030 例乳腺癌患者中有 750 例(发生率 0.10%)为 T0N+M0 疾病,其中 596 例患者接受了 ALND。接受 Mast 或 BCT(n=470)的患者 10 年 OS 率为 64.9%,而仅接受 ALND(n=126)的患者为 58.5%(P=0.02),仅接受观察的患者为 47.5%(n=94;P=0.04)。接受 BCT 的患者 10 年 CSS 率为 75.7%,而接受 Mast 的患者为 73.9%(P=0.55)。对接受 Mast 或 BCT 的患者进行 CSS 的多变量分析,以下因素与不良结局相关:雌激素受体阳性状态(风险比[HR],0.48;95%置信区间[CI],0.24-0.96;P=0.04)、>10 个阳性淋巴结(HR,5.7;95%CI,2.4-13.4;P=0.01)和<10 个切除淋巴结(HR,42.9;95%CI,1.2-7.1;P=0.02)。与 BCT 相比,Mast 并未改善 CSS(HR,1.09;95%CI,0.57-2.1;P=0.79)。
采用 Mast 或 BCT 进行确定性局部区域治疗可改善 T0N+乳腺癌患者的结局,且两种治疗方法之间的生存率无差异。癌症 2010。(c)2010 年美国癌症协会。